Alnylam halts drug's development after patient deaths in study

Alnylam Pharmaceuticals will stop developing an experimental drug after a late-stage study showed patients given the treatment were more likely to die than those given a placebo, reports Reuters.

The Cambridge, Mass.-based drugmaker was developing revusiran for the treatment of hereditary amyloidosis with cardiomyopathy — a rare condition in which amyloid plaque collects in the organs and can cause heart failure, according to the report.

The company decided to suspend a Phase III trial of the drug after unblinded data from a previous trial "revealed an imbalance of mortality in the revusiran arm as compared to placebo," according to a company statement.

Upon news of the halted drug development, Alnylam's shares dropped more than 40 percent to $40.96 in post-market trading after closing at $70.30 on Wednesday.

More articles on supply chain:

FedEx to open new Ohio distribution center in 2017
Novartis restructures research unit, sheds 175 jobs: 4 things to know
Insmed buys AstraZeneca's respiratory drug for $150M: 5 things to know

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers